global-development series fair-access 
Pharmaceutical Technology
MAY 17, 2023
The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. Meanwhile, the panellists also discussed how the Inflation Reduction Act, or the IRA, would impact drug development for rare diseases.
pharmaphorum
DECEMBER 22, 2021
As part of our 2021 in Review series, we look back over some of these developments. Education and empowerment allow for equal access to care. She set the scene by saying she owed her life to experimental treatments she was only able to access because of her microbiology background.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 28, 2020
The federal government, in partnership with state health departments, is developing a government allocation program for bamlanivimab. Ricks has said that the company “must work with global health systems to ensure equitable access to our medicine at a fair price”.
pharmaphorum
SEPTEMBER 30, 2020
“For companies like us, it is important to provide some solutions to ensure access to innovation, to act with responsibility and integrity and to be committed to patients and to Europe”. It is equally fair to say that new technologies – besides the opportunities they represent – come together with their share of risks and disruptions.
pharmaphorum
NOVEMBER 16, 2021
In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their uptake in England rather than looking at a small set of medicines and their uptake internationally. Set a clear target from the outset.
pharmaphorum
FEBRUARY 4, 2022
In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among payers in England, comparing assessments by NICE versus the NHS. per 10,000).
Pharma Marketing Network
NOVEMBER 4, 2020
I have with me today Tom Ollerton from Automated Creative which is doing some really fascinating things when it comes to applying artificial intelligence to the creative development process in measuring process. Welcome Tom. RJ (PMN): I’m glad you could make it. RJ (PMN): Interesting. Tom (AC): No.
Expert insights. Personalized for you.
52 
Let's personalize your content